- Conditions
- Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Interventions
- GI-102, Pasritamig
- Drug
- Lead sponsor
- GI Innovation, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 265–288
of 768
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- CART-PSMA-TGFβRDN, Cyclophosphamide, Fludarabine, Anakinra
- Biological · Drug
- Lead sponsor
- Tceleron Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 9
- States / cities
- Tampa, Florida • Kansas City, Kansas • St Louis, Missouri + 5 more
- Conditions
- Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Lymph Nodes, Stage IVB Prostate Cancer AJCC v8
- Interventions
- Avelumab, Biospecimen Collection, Bone Scan, Computed Tomography, Magnetic Resonance Imaging, Peposertib, Questionnaire Administration, Radium Ra 223 Dichloride
- Drug · Procedure · Other + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 32
- States / cities
- Duarte, California • Los Angeles, California • Orange, California + 24 more
- Conditions
- Prostate Cancer
- Interventions
- Placebo, Metformin
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- SX-682, Enzalutamide
- Drug
- Lead sponsor
- Syntrix Biosystems, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 6
- States / cities
- Los Angeles, California • San Francisco, California • Ann Arbor, Michigan + 3 more
- Conditions
- Advanced Metastatic Castration-resistant Prostate Cancer, Prostate Specific Membrane Antigen (PSMA) Expression
- Interventions
- 225Ac-PSMA-Trillium (BAY3563254)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 198 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2032
- U.S. locations
- 4
- States / cities
- Duarte, California • Minneapolis, Minnesota • Omaha, Nebraska + 1 more
- Conditions
- Advanced Solid Tumor
- Interventions
- DB-1305/BNT325, Pembrolizumab, BNT327
- Drug · Combination Product
- Lead sponsor
- DualityBio Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 42
- States / cities
- Bullhead City, Arizona • Cerritos, California • La Jolla, California + 34 more
- Conditions
- Prostate Cancer
- Interventions
- VT-464: given orally twice daily in 28-day cycles, VT-464: given orally once daily in 28-day cycles
- Drug
- Lead sponsor
- Innocrin Pharmaceutical
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Metastatic Castration-Resistant Prostate Cancer
- Interventions
- AAA617, Gonadotropin-releasing hormone (GnRH) analogues, Gonadotropin-releasing hormone (GnRH) antagonists
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years · Male only
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Palo Alto, California • Rochester, Minnesota + 2 more
- Conditions
- Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
- Interventions
- Carboplatin, Docetaxel
- Drug
- Lead sponsor
- Seattle Institute for Biomedical and Clinical Research
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Ann Arbor, Michigan • Seattle, Washington
- Conditions
- Renal Cell Carcinoma, Urothelial Carcinoma, Castration-resistant Prostate Cancer
- Interventions
- DCC-2812
- Drug
- Lead sponsor
- Deciphera Pharmaceuticals, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 8
- States / cities
- Boston, Massachusetts • Ann Arbor, Michigan • St Louis, Missouri + 5 more
- Conditions
- Metastatic Castration Resistant Prostate Cancer
- Interventions
- Enzalutamide
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 5
- States / cities
- Evanston, Illinois • Worcester, Massachusetts • New York, New York + 2 more
- Conditions
- Prostate Cancer, Castration-resistant, Metastatic
- Interventions
- testosterone (AndroGel®) with the 5α-reductase inhibitor dutasteride
- Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v7, Metastatic Malignant Neoplasm in the Bone
- Interventions
- Carboplatin, Docetaxel, Laboratory Biomarker Analysis, Sirolimus
- Drug · Other
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Prostate Cancer, Refractory Cancer, Castration Resistant Prostatic Cancer
- Interventions
- Omeprazole 80 mg twice daily
- Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 2
- States / cities
- Salisbury, North Carolina • Winston-Salem, North Carolina
- Conditions
- Prostate Cancer
- Interventions
- Docetaxel, Prednisone, LDE225
- Drug
- Lead sponsor
- Martin Gutierrez
- Other
- Eligibility
- 18 Years and older · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Hackensack, New Jersey
- Conditions
- Prostate Cancer
- Interventions
- Ipilimumab
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 11
- States / cities
- San Francisco, California • Washington D.C., District of Columbia • Jacksonville, Florida + 8 more
- Conditions
- Metastatic Castrate Resistant Prostate Cancer
- Interventions
- Docetaxel, Radium 223
- Drug · Radiation
- Lead sponsor
- Tufts Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • Detroit, Michigan • Columbus, Ohio
- Conditions
- Prostate Cancer
- Interventions
- BMS-986165, Degarelix
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 6
- States / cities
- Basking Ridge, New Jersey • Montvale, New Jersey • Commack, New York + 3 more
- Conditions
- Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer
- Interventions
- Docetaxel, Lycopene
- Drug · Dietary Supplement
- Lead sponsor
- University of California, Irvine
- Other
- Eligibility
- 21 Years and older · Male only
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 1
- States / cities
- Orange, California
- Conditions
- Prostate Cancer
- Interventions
- CTT1057, Prostatectomy
- Drug · Procedure
- Lead sponsor
- Cancer Targeted Technology
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- FPI-2265
- Drug
- Lead sponsor
- Fusion Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 18
- States / cities
- Duarte, California • Irvine, California • Los Angeles, California + 12 more
- Conditions
- Prostate Cancer
- Interventions
- 225Ac-J591
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 2
- States / cities
- New Orleans, Louisiana • New York, New York
- Conditions
- Prostate Cancer, Castration Resistant Prostate Cancer, Prostatic Neoplasms
- Interventions
- cabozantinib, abiraterone, prednisone
- Drug
- Lead sponsor
- Exelixis
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 20
- States / cities
- Scottsdale, Arizona • Sedona, Arizona • Tucson, Arizona + 16 more